Table 2.
Malignant networks also are partly activated by oxaliplatin treatment, indicating an inherent competition between efficacy and toxicity which can be characterized based on high throughput analysis
|
Overview of some signaling changes upon oxaliplatin treatment | |||
|---|---|---|---|
| Signaling network | Molecules in dataset | # Up regulated | # Down regulated |
| Ovarian Cancer |
64 |
34 |
30 |
| Glioma Signaling |
50 |
26 |
24 |
| Prostate Cancer |
53 |
31 |
22 |
| Non-Small Cell Lung Cancer |
39 |
25 |
14 |
| Colorectal Cancer Metastasis |
116 |
59 |
57 |
| Basal Cell Carcinoma |
25 |
13 |
12 |
| Melanoma |
25 |
14 |
11 |
| Small Cell Lung Cancer |
47 |
28 |
19 |
| VEGF |
49 |
25 |
24 |
| Renal Cell Carcinoma |
45 |
30 |
15 |
| Sonic Hedgehog |
15 |
7 |
8 |
| Pancreatic Adenocarcinoma | 65 | 37 | 28 |